SGLT-2 inhibitors were linked to lower risk for autoimmune rheumatic diseases in those with diabetes compared with sulfonylureas.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback